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1. Introduction 
Many analogs of luteinizing hormone-releasing 
hormone (LH-RH) have been recently synthesized 
in order to investigate the significance of the various 
constituent amino acids in hormonal activity [ 1 ] . 
Assessments of the capacity of analogs to stimulate 
release of LH and FSH have revealed that arginine in 
position 8 on the peptide chain is critical for eliciting 
full activity [2-51. It was suggested that the basic 
guanidine side-chain of arginine participates in the 
binding of LH-RH to its specific pituitary receptor 
site via an ionic interaction [5] and probably by a 
hydrogen-bond formation mechanism, as well [3]. 
It was also postulated, based on fluorescence studies, 
that the importance of arginine is due to its location 
in the tertiary structure of the LH-RH molecule 
itself, that is, in the assembly of the amino acids His’, 
Tyr’, and Arg8 which exist as a close-knit unit, 
probably playing an active role in the hormonal action 
of the peptide [6,7]. The structural function of Arg* 
was also suggested by binding studies of LH-RH and 
several of its analogs to plasma membranes of the 
anterior pituitary [8] . 
To gain further understanding of the function of 
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arginine, we prepared and tested the LH-releasing 
activity and the cross-reactivity with anti-LH-RH 
antibodies of two new analogs of LH-RH. The 
analogs synthesized were (w-NO*-Arg*)-LH-RH, a 
derivative in which the positive charge of the guanidine 
group is totally neutralized, and (DHCH-Arg*)- 
LH-RH in which the positive character is preserved, 
while the size of the guanidine is markedly increased. 
Studies of these analogs support the suggestion as to 
the structural role of Arg* in LH-RH. 
2. Materials and methods 
Synthetic LH-RH was a generous gift of Ayerst 
Research Laboratories Saint-Laurent, Canada. 1,2- 
Cyclohexanedione was purchased from Aldrich Chemi- 
cal Company, Milwaukee, USA. 
2.1. Synthesis of arginine group (I) analogs of LH-RH 
2.2.1. (o-NOz--Arg* )--LH-RH (II) 
p-Glu-His-Trp-Se-Tyr-Gly-Leu-Arg(NOz)- 
Pro-Gly-OH (E. Hazum and M. Fridkin, unpublished) 
20 mg, was allowed to couple for 60 min at 0°C in 
dry DMF (1 ml) with N-hydroxy-succinimide (15 mg), 
using WV’-dicyclohexylcarbodiimide (25 mg) as the 
coupling agent. Dry ammonia was then bubbled 
through the solution for 10 min at 0°C and the crude 
(o-NOz--Args)-LH-RH obtained by evaporation of 
solvent was purified on a CMC-23 column. Excesses of 
a starting material were eluted with 0.1 mM NH4Ac 
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(pH 6.52), while the product was released using 
0.01 M NH‘,Ac (pH 6.52). 
2.1.2. (DHCH-Arg’)-LH-RH (III) 
(DHCH-Args)-LH-RH (III) was prepared accord- 
ing to Patthy and Smith [9] by reacting LH-RI-I 
(5 mg) with 1,2-cyclohexanedione (20 mg) in sodium 
borate buffer (0.2 M, pH 9.0,0.5 ml) under nitrogen 
in the dark at room-temperature for 24 h. Purifica- 
tion of the crude product was performed by gel- 
filtration on a Sephadex G-l 0 column using 1 .O M 
acetic acid as eluent. 
2.2. Biological assay 
Pituitaries from twelve-day-old female rats were 
placed in 1 ml of Krebs-Ringer bicarbonate (KRB, 
pH 7.4) containing lucose (1 mg/ml) and initially 
incubated for 2 h at 37°C under an atmosphere of
95% 02:5% COZ. This medium was then substituted 
by 1 ml KRB containing LH-RH or an LH-RH analog 
(1 X lo-‘-5 X 10.’ M), and incubation was continued 
for 90 min. Aliquots of the medium were then ana- 
lyzed for LH by radioimmunoassay, using the kit 
kindly supplied by the National Institute of Arthritis 
and Metabolism and Digestive Diseases (NIAMDD), 
rat pituitary hormone program. 
3. Results and discussion 
Two analogs of LH-RH (I) were prepared in which 
the arginine residue in position 8 was modified: 
(w-NOz--Arg*)-LH-RI-I (II) and (DHCH-Arg’)- 
LH-RI-I (III) (see fig.1). The two peptides were homo- 
geneous when checked by thin-layer chromatography, 
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Fig.1. Structures of arginine residue in LH-RH (I) and of 
modified arginine residues in (w-nitro-Arg’)-LH-RH (II) 
and in (DHCH-Arg’)-LH-RH (III). 
using various olvent systems, as well as by paper 
electrophoresis (table 1). Both are positively stained 
by Pauli reagent for histidine and tyrosine and by 
Ehrlich reagent for tryptophan, but give negative 
reaction with Sakaguchi reagent for arginine. Their 
acid hydrolysates contained the constituent amino 
acids in ratios close to the theoretical (table 1). 
The LH-releasing activities of II and III were ’ 
assessed in several dose-levels and found to be 0.8% 
and 2.4% of LH-RI-I, respectively. The exceedingly 
low biological activity of II correlates with its being 
poorly recognized (<I%) by antibodies pecific to 
LH-RI-I [lo] . The above, coupled with the finding 
that the fluorescence properties of II are markedly 
different from those of LH-RH [7], suggests hat the 
neutralization of the positive charge of arginine 
resulted in a loss of the major structural features of 
the parent peptide. The somewhat higher activity of 
III is in line with its being better recognized by anti- 
LH-RI-I antibodies (20-25%) and with the fact that 
its fluorescence properties (E. Hazum and M. Fridkin, 
unpublished) are not very different from those of 
LH-RH and are similar to those of (Lys*)-LH-RH 
[7] . This latter analog has a substantial LH-releasing 
activity [2,3] and it highly cross-reacts (SO-loo%) 
with anti-LH-RH antibodies [7 ] . Although some of 
the essential features of LH-RI-I were probably 
preserved in (DHCH-Arg8)-LH-RH, it is reasonable 
to assume that masking the positive charge of 
arginine with the bulky DHCH-group led to changes 
in the three-dimensional structure of LH-RH. 
Hence, it seems plausible that the function of 
positively charged arginine in position 8 of LH-RH 
is to stabilize the preferred conformation of the 
molecule necessary for its normal biological 
functioning. 
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